Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Active, not recruiting · NCT07184840 · Registry updated 2026-06-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Active, not recruiting | Phase 2 | 2026-06-03 | NCT07184840 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University General Hospital | 80 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University General Hospital | Tianjin | China | 61 |